Skip to main content

Table 3 Multivariate analysis PFS

From: NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

MULTIVARIATE ANALYSIS (PFS)
  HR 95 % CI p
KPS 2,18 0,8–5,9 0,125
CA19.9 RESPONSE 0,27 0,1–0,68 0,006
NLR ≥ 5 3,84 1,6–9,2 0,002
BILIRUBIN 1,4 0,59–3,3 0,444